scout
Opinion|Videos|April 25, 2024

Overall Survival and Progression Free Survival in the FRESCO-2 Trial

Arvind Dasari, MD, examines the progression-free survival and overall survival data from the FRESCO-2 trial, comparing the results to the original FRESCO trial, and discussing the implications for the treatment of heavily pretreated metastatic colorectal cancer patients.

Newsletter

Stay up to date on practice-changing data in community practice.

Latest CME